Equities

VIDEO: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial

Video thumbnail
Video Player is loading.
Current Time 0:15
Duration 7:07
Loaded: 14.01%
Stream Type LIVE
Remaining Time 6:52
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • default, selected

    Paradigm Biopharmaceuticals is currently conducting a global, Phase 3 clinical trial for its iPPS treatment for osteoarthritis (OA).

    In this interview, Paradigm Biopharmaceuticals Managing Director Paul Rennie discusses the potential for the company’s breakthrough treatment to break into the $8.28 billion global market for osteoarthritis therapeutics. 

    Paradigm has cashed up, having raised $30.1 million in October last year to develop its iPPS treatment for the disease.

    Disclaimer
    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
    Publisher
    Paradigm Biopharmaceuticals